Skip to main
OSTX

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. demonstrates a strong positive outlook due to its successful engagement with the FDA, where it clarified a potential pathway for the accelerated approval of its lead candidate, OST-HER2, in treating metastatic osteosarcoma. Additionally, the company achieved full regulatory alignment with the UK MHRA, marking a significant milestone that enhances its prospects for conditional approval in the UK market. The emphasis on leveraging immune-response biomarker data from both canine and human trials supports the company’s innovative approach and positions it favorably within the biopharmaceutical landscape.

Bears say

OS Therapies Inc's focus on developing treatments for osteosarcoma faces significant scientific challenges, as the disease does not respond well to receptor-level HER2 inhibition, which undermines the effectiveness of potential therapies. Furthermore, osteosarcoma is characterized as immunologically "cold," genetically unstable, and poorly responsive to antibody-based treatments, which raises concerns about the viability of the company's drug development pipeline. These fundamental issues in addressing the specific nature of osteosarcoma could hinder the company's ability to achieve successful commercialization and attract investor confidence.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.